Sana Biotechnology Updates ATM Program to Support Development

Sana Biotechnology ( (SANA) ) just unveiled an update.

Sana Biotechnology, Inc., based in Seattle and listed on Nasdaq as SANA, operates in the biotechnology industry, focusing on creating and delivering engineered cell and gene therapies. The company’s key platforms include its hypoimmune technology for allogeneic cell therapies such as pancreatic islet cell treatments for type 1 diabetes, and its fusogen delivery platform for in vivo CAR T and gene-editing approaches targeting cancers and autoimmune diseases.

Sana Biotechnology reported fourth-quarter and full-year 2025 results on March 3, 2026, highlighted by 12‑month data from the UP421 type 1 diabetes study showing safe, durable, immunosuppression‑free function of hypoimmune‑modified pancreatic islet cells, with early study results published in the New England Journal of Medicine. The company advanced lead programs SC451 for type 1 diabetes and SG293 for in vivo CAR T treatment of blood cancers and B‑cell‑mediated autoimmune diseases, strengthened its balance sheet with $133.7 million in 2025 equity proceeds for a cash position of $138.4 million and runway into late 2026, reduced R&D expenses following portfolio prioritization, entered an amended at‑the‑market sales agreement of up to $150 million, and appointed veteran biotech finance executive Brian Piper as chief financial officer.

On March 3, 2026, Sana amended and restated its at‑the‑market equity sales agreement with TD Securities (USA) LLC to allow controlled, periodic sales of common stock, replacing a May 8, 2025 facility under which it had already raised $45.8 million. The new arrangement, supported by a pending $150 million shelf registration, gives Sana flexible access to additional capital while preserving discretion over timing, size, and pricing of issuances, and underscores its intent to fund parallel clinical development of its hypoimmune and fusogen platforms without committing to a specific equity raise timetable.

The most recent analyst rating on (SANA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.

Spark’s Take on SANA Stock

According to Spark, TipRanks’ AI Analyst, SANA is a Neutral.

Overall score is held back primarily by weak financial fundamentals typical of a development-stage biotech (no revenue, large losses, and continued cash burn with higher leverage). Technicals are moderately supportive with the stock trading above major moving averages and mild positive momentum, while valuation remains challenged due to negative earnings. A positive corporate update on diabetes cell-therapy progress provides an additional tailwind but does not offset the funding and execution risk implied by current financials.

To see Spark’s full report on SANA stock, click here.

More about Sana Biotechnology

Sana Biotechnology, Inc., based in Seattle and listed on Nasdaq as SANA, operates in the biotechnology industry, focusing on creating and delivering engineered cell and gene therapies. The company’s key platforms include its hypoimmune technology for allogeneic cell therapies such as pancreatic islet cell treatments for type 1 diabetes, and its fusogen delivery platform for in vivo CAR T and gene-editing approaches targeting cancers and autoimmune diseases.

Sana Biotechnology reported fourth-quarter and full-year 2025 results on March 3, 2026, highlighted by 12‑month data from the UP421 type 1 diabetes study showing safe, durable, immunosuppression‑free function of hypoimmune‑modified pancreatic islet cells, with early study results published in the New England Journal of Medicine. The company advanced lead programs SC451 for type 1 diabetes and SG293 for in vivo CAR T treatment of blood cancers and B‑cell‑mediated autoimmune diseases, strengthened its balance sheet with $133.7 million in 2025 equity proceeds for a cash position of $138.4 million and runway into late 2026, reduced R&D expenses following portfolio prioritization, entered an amended at‑the‑market sales agreement of up to $150 million, and appointed veteran biotech finance executive Brian Piper as chief financial officer.

On March 3, 2026, Sana amended and restated its at‑the‑market equity sales agreement with TD Securities (USA) LLC to allow controlled, periodic sales of common stock, replacing a May 8, 2025 facility under which it had already raised $45.8 million. The new arrangement, supported by a pending $150 million shelf registration, gives Sana flexible access to additional capital while preserving discretion over timing, size, and pricing of issuances, and underscores its intent to fund parallel clinical development of its hypoimmune and fusogen platforms without committing to a specific equity raise timetable.

Average Trading Volume: 3,112,620

Technical Sentiment Signal: Hold

Current Market Cap: $1.11B

See more insights into SANA stock on TipRanks’ Stock Analysis page.